<SEC-DOCUMENT>0001638833-25-000166.txt : 20251112
<SEC-HEADER>0001638833-25-000166.hdr.sgml : 20251112
<ACCEPTANCE-DATETIME>20251112172415
ACCESSION NUMBER:		0001638833-25-000166
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		13
CONFORMED PERIOD OF REPORT:	20251112
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20251112
DATE AS OF CHANGE:		20251112

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Surgery Partners, Inc.
		CENTRAL INDEX KEY:			0001638833
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-GENERAL MEDICAL & SURGICAL HOSPITALS, NEC [8062]
		ORGANIZATION NAME:           	08 Industrial Applications and Services
		EIN:				473620923
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37576
		FILM NUMBER:		251474370

	BUSINESS ADDRESS:	
		STREET 1:		310 SEVEN SPRINGS WAY
		STREET 2:		SUITE 500
		CITY:			BRENTWOOD
		STATE:			TN
		ZIP:			37027
		BUSINESS PHONE:		615-234-5900

	MAIL ADDRESS:	
		STREET 1:		310 SEVEN SPRINGS WAY
		STREET 2:		SUITE 500
		CITY:			BRENTWOOD
		STATE:			TN
		ZIP:			37027
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>sgry-20251112.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:b54ad9c4-2ac7-45a7-af50-9ccb8cd7b891,g:e49025d9-fcc2-48e1-a74f-bcebcf2d0f82,d:15c71ca663dc47d0921ae3136734146a-->
<html xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns="http://www.w3.org/1999/xhtml" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>sgry-20251112</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-24">0001638833</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" format="ixt:fixed-false" id="f-25">FALSE</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="sgry-20251112.xsd"/></ix:references><ix:resources><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-11-12</xbrli:startDate><xbrli:endDate>2025-11-12</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i15c71ca663dc47d0921ae3136734146a_1"></div><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"/></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:18pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:18pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="margin-bottom:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="margin-bottom:6pt;margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:18pt;font-weight:700;line-height:120%">Form <ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">8-K</ix:nonNumeric></span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">CURRENT REPORT</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.638%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:100%">Date of Report (Date of earliest event reported):   <ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-2">November&#160;12, 2025</ix:nonNumeric></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:18pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-3">Surgery Partners, Inc.</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(Exact Name of Registrant as Specified in Charter)</span></td></tr></table></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.500%"><tr><td style="width:1.0%"/><td style="width:32.083%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.084%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="f-4">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-5">001-37576</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityTaxIdentificationNumber" id="f-6">47-3620923</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(State or Other Jurisdiction<br/>of Incorporation)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(Commission<br/>File Number)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(IRS Employer<br/>Identification No.)</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-7"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-8">340 Seven Springs Way, Suite&#160;600</ix:nonNumeric></ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-9"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-10">Brentwood</ix:nonNumeric></ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="f-11">Tennessee</ix:nonNumeric> <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-12">37027</ix:nonNumeric></span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">(Address of Principal Executive Offices) (Zip Code)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="c-1" name="dei:CityAreaCode" id="f-13">615</ix:nonNumeric>) <ix:nonNumeric contextRef="c-1" name="dei:LocalPhoneNumber" id="f-14">234-5900</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">(Registrant&#8217;s Telephone Number, Including Area Code)</span></div><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:WrittenCommunications" format="ixt-sec:boolballotbox" id="f-15">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:SolicitingMaterial" format="ixt-sec:boolballotbox" id="f-16">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementTenderOffer" format="ixt-sec:boolballotbox" id="f-17">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementIssuerTenderOffer" format="ixt-sec:boolballotbox" id="f-18">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="margin-bottom:9pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.444%"><tr><td style="width:1.0%"/><td style="width:33.164%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.811%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.547%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.811%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:33.167%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:Security12bTitle" id="f-19">Common Stock, par value $0.01 per share</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:TradingSymbol" id="f-20"><ix:nonNumeric contextRef="c-1" name="dei:TradingSymbol" id="f-21">SGRY</ix:nonNumeric></ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-22">The Nasdaq Global Select Market</ix:nonNumeric></span></td></tr></table></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Emerging growth company     </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" id="f-23">&#9744;</ix:nonNumeric></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.     </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-bottom:8pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"/></tr></table></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i15c71ca663dc47d0921ae3136734146a_7"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">Item 5.02.  Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Appointment of Justin Oppenheimer as Chief Operating Officer and National Group President</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">On November&#160;12, 2025, Surgery Partners, Inc. (the &#8220;Company&#8221;) announced the appointment of Justin Oppenheimer to serve as Chief Operating Officer and National Group President of the Company, effective as of January 1, 2026.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Mr. Oppenheimer, age 41, joins Surgery Partners from the Hospital for Special Surgery (HSS), where he spent the past decade in a variety of leadership roles, including Chief Strategy Officer and Chief Operating Officer. He also serves on the Board of Directors for Urban Dove, a New York-based charter school management organization. He holds a B.A. degree in political economy from Princeton University, and an MBA from Harvard Business School.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Employment Agreement with Justin Oppenheimer</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Mr. Oppenheimer's Employment Agreement is incorporated into this Item 5.02 by reference to Exhibit 10.1 of this Current Report on Form 8-K.</span></div><div id="i15c71ca663dc47d0921ae3136734146a_10"></div><div style="-sec-extract:summary;margin-bottom:9pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Item 9.01. Financial Statements and Exhibits. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(d) Exhibits: </span></div><div style="margin-bottom:5pt;margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.859%"><tr><td style="width:1.0%"/><td style="width:8.401%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.578%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:88.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit101oppenheimeremplo.htm">10.1</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit101oppenheimeremplo.htm">Justin Oppenheimer</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit101oppenheimeremplo.htm"> </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit101oppenheimeremplo.htm">Employment Agreement</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit101oppenheimeremplo.htm"> dated </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit101oppenheimeremplo.htm">October 27, 2025</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (embedded within the Inline XBRL document)</span></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i15c71ca663dc47d0921ae3136734146a_13"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span></div><div style="margin-bottom:8pt;margin-top:5pt;padding-left:180pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:333.00pt"><tr><td style="width:1.0pt"/><td style="width:22.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:306.25pt"/><td style="width:1.0pt"/></tr><tr style="height:14pt"><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">SURGERY PARTNERS,&#160;INC.</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:35pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">/s/  David T. Doherty</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">David T. Doherty</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Executive Vice President, Chief Financial Officer</span></div></td></tr></table></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Date:  November&#160;12, 2025</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>exhibit101oppenheimeremplo.htm
<DESCRIPTION>EX-10.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="i7106d3d25503427b80a0b06260615b5d_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:100%">Exhibit 10.1</font></div></div><div style="margin-bottom:12pt;padding-left:18pt;padding-right:18pt;text-align:center;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">EMPLOYMENT AGREEMENT</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">THIS EMPLOYMENT AGREEMENT (this &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Agreement</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) is hereby entered into effective as of October 27, 2025 (the &#8220;Effective Date&#8221;), between Surgery Partners, Inc. (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Company</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) and Justin Oppenheimer (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Executive</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">1.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Employment</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.  The Company shall employ Executive, and Executive hereby accepts continued employment with the Company, upon the terms and conditions set forth in this Agreement for the period beginning on January 1, 2026 or such earlier date as mutually agreed to by the parties hereto (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Commencement Date</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) and ending on the Termination Date, as provided for in Section 4 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Employment Period</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;).  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">2.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Position and Duties</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.7pt">During the Employment Period, Executive shall serve as the Executive Vice President, Chief Operating Officer and National Group President reporting to the Chief Executive Officer.  Executive shall have such responsibilities, duties and authorities, and will render such services for the Company and its Subsidiaries or Affiliates as the Board of Directors of the Company (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Board</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) may from time to time direct.  Executive will devote his best efforts, energies and abilities and his full business time, skill and attention to the business and affairs of the Company and its Subsidiaries, and shall perform his duties and responsibilities to the best of his ability, in a diligent, trustworthy, businesslike and efficient manner for the purpose of advancing the businesses of Company and its Subsidiaries.  Executive acknowledges that his duties and responsibilities will require his full time business efforts and agrees that during the Employment Period he will not engage in any other business activity or have any business pursuits that interfere with Executive&#8217;s duties and responsibilities under this Agreement or are competitive with the businesses of the Company.  Notwithstanding the foregoing, Executive shall be permitted to devote a reasonable amount of time and effort to (i) providing service to, or serving on governing boards of, civic and charitable organizations and any other organizations approved by the Company&#8217;s Board of Directors, Chief Executive Officer and Chief Compliance Officer, and (ii) personally investing and managing personal and family investments in real estate and in any corporation, partnership or other entity&#59; but in each case, only to the extent that any of the activities described in clauses (i) or (ii), individually or as a whole, do not (A) require or involve the active participation of Executive in the management of any corporation, partnership or other entity or interfere with the execution of Executive&#8217;s duties hereunder, or (B) otherwise violate any provision of this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.02pt">For purposes of this Agreement, (i) &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Subsidiaries</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means any corporation or other entity (A) of which the securities or other ownership interests having the voting power to elect a majority of the board of directors or other governing body are, at the time of determination, owned by the Company, directly or through one or more subsidiaries or (B) to which the Company or any of its Affiliates provide management services, and (ii) &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Affiliate</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; of an entity means any other person or entity, directly or indirectly controlling, controlled by or under common control with an entity.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">3.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Compensation and Benefits</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.7pt">During the Employment Period, Executive&#8217;s base salary shall be $660,000 per annum, payable by the Company in regular installments in accordance with the Company&#8217;s general payroll practices, less taxes and other applicable withholdings, and subject to review and adjustment from time to time by the Board or the Compensation Committee thereof (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Committee</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), in either case, in its discretion (as modified from time to time, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Base Salary</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.02pt">Within 30 days after the Commencement Date, the Company will provide the Executive with a cash payment of $500,000&#59; provided, however, that, if the Executive resigns his employment without Good Reason (other than a termination due to death or Incapacity) or the Company terminates </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">Executive&#8217;s employment for Cause (as such terms are defined in Section 4), in either event prior to the first anniversary of the Commencement Date, the Executive will repay the net amount of the Signing Bonus immediately upon the end of the Employment Period.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.7pt">In addition, during the Employment Period, Executive shall be entitled to participate in all of the Company&#8217;s benefit programs for which employees of the Company are generally eligible, subject to the eligibility and participation requirements thereof, including, but not limited to, the following&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:24.69pt">medical, dental, vision, life and disability insurance, as is generally provided to other employees of the Company&#59; and</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:21.36pt">eligibility for vacation time in accordance with the policies of the Company as from time to time in effect&#59; provided, however, that Executive shall not have less than 20 days of vacation time per calendar year.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.02pt">During the Employment Period, the Company shall reimburse Executive for all reasonable out-of-pocket expenses incurred by him in the course of performing his duties and responsibilities under this Agreement which are consistent with the Company&#8217;s policies in effect from time to time with respect to travel, entertainment and other business expenses, subject to the Company&#8217;s requirements with respect to reporting and documentation of such expenses. Executive&#8217;s right to payment or reimbursement for business expenses hereunder will be subject to the following additional rules&#58; (i) no reimbursement of any expense shall affect Executive&#8217;s right to reimbursement of any other expense in any other taxable year&#59; (ii) the amount of expenses eligible for payment or reimbursement during any calendar year will not affect the expenses eligible for payment or reimbursement in any other taxable year&#59; (iii) payment or reimbursement will be made not later than December 31 of the calendar year following the calendar year in which the expense was incurred or paid, and (iv) the right to payment or reimbursement is not subject to liquidation or exchange for any other benefit.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.7pt">In addition to the Base Salary, Executive will be eligible to receive an annual bonus of 100% of the Base Salary, with the actual amount of any such bonus being determined by the Board or the Committee, in either case, in its discretion, based on the achievement of performance goals established annually by the Board or the Committee, as applicable.  Any annual bonus payable under this Section 3(d) will be paid no later than March 31</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:7.15pt;font-weight:400;line-height:100%;position:relative;top:-3.85pt;vertical-align:baseline">st</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%"> following the close of the year for which the bonus is earned.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">(f)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:24.03pt">Executive shall be eligible to participate in the Surgery Partners, Inc. 2025 Omnibus Incentive Plan (as amended from time to time) (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Plan</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) on terms and conditions set forth therein and in the relevant award agreement unless specifically stated otherwise in this Agreement, and will be eligible for annual equity grants under the Plan. The number of shares subject to each award will be determined by reference to the fair market value of the Company&#8217;s common stock on the date of the grant of the award.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.69pt">Commencing in calendar year 2026, Executive will be eligible for annual equity grants under the Plan with an annual target amount of $1,500,000 (subject to approval of the Board (or an authorized committee thereof), in such forms as determined by the Board or its designee in its discretion.  </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.36pt">As soon as reasonably practicable following the Commencement Date, the Company shall provide an equity grant to the Executive of $1,250,000 in a restricted stock award that vests on the first anniversary of such award.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">(g)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.02pt">All amounts payable to Executive hereunder shall be subject to all required withholdings by the Company.  If additional guidance is issued under, or modifications are made to, Section 409A of the Internal Revenue Code of the Internal Revenue Code and the regulations and other interpretive </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;-2-</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">guidance issued thereunder (collectively, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 409A</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), or any other law affecting payments to be made under this Agreement, Executive agrees that the Company may take such reasonable actions and adopt such reasonable amendments as the Company believes are necessary to ensure continued compliance with the Internal Revenue Code, including Section 409A.  However, the Company does not hereby or otherwise represent or warrant that any payments hereunder are or will be in compliance with Section 409A, and Executive shall be responsible for obtaining his own tax advice with regard to such matters.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">4.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Termination</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">Termination by Executive or the Company</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.  The Employment Period (i) shall terminate upon Executive&#8217;s resignation with Good Reason (as defined below) or without Good Reason, death or Incapacity (as defined below) or (ii) may be terminated by the Company at any time for Cause (as defined below) or without Cause. If the Company terminates this Agreement without Cause at any point after the Effective Date but prior to the beginning of the Employment Period, such termination shall be considered a termination by the Company without Cause.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.02pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Good Reason</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; shall mean without the written consent of Executive&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:24.69pt">without the express written consent of Executive, a material diminution of his position, duties, responsibilities, and status with the Company as in effect as of the Commencement Date or a material reduction of Executive&#8217;s resources as in effect on the Commencement Date&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:21.36pt">a material reduction in Executive&#8217;s Base Salary or annual bonus target percentage&#59; </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:18.03pt">a material reduction in the level of benefits available or awarded to Executive, other than any reduction in connection with a Company-wide reduction applicable generally to similarly situated executive officers of the Company&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">(iv)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:18.69pt">within twelve months of a Change in Control (as defined herein), a material increase in Executive&#8217;s core functional responsibilities with a corresponding material change in Executive&#8217;s core functional role without a corresponding increase in compensation, provided, however, the addition of additional facilities or territories to Executive&#8217;s oversight responsibilities or other ordinary course growth of the Company or any of its Subsidiaries or Affiliates shall not be a material increase in Executive&#8217;s core functional responsibilities&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">(v)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.02pt">a relocation by the Company of Executive&#8217;s primary employment location to a location which is more than 50 miles from Executive&#8217;s primary employment location on the date hereof&#59; or</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">(vi)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:18.69pt">a material breach by the Company of the terms of this Agreement, which shall include, without limitation, a change from Executive reporting directly to the Chief Executive Officer&#59; </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">but only if (x) Executive notifies the Company in writing within 90 days after the initial existence or occurrence of any of these conditions which notice describes in reasonable detail the basis for Executive&#8217;s belief that Good Reason exists and that Executive intends to resign for Good Reason and the Company, within 30 days after receipt of such notice, either fails to cure the condition or delivers a written notice to Executive that the Company intends not to cure such condition and (y) Executive actually resigns prior to 15 days after the earlier to occur of either the end of such 30-day cure period or delivery of such written notice by the Company.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;-3-</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.7pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Incapacity</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; as used herein shall mean that Executive is unable to perform, with or without reasonable accommodation, by reason of physical or mental incapacity, the essential duties, responsibilities and functions of his position.  A medical examination by a physician selected by the Company to whom Executive or his duly appointed guardian, if any, has no reasonable objection shall determine, according to the facts then available, whether and when Incapacity has occurred.  Such determination shall not be arbitrary or unreasonable, and shall be final and binding on the parties hereto.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.02pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Cause</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; as used herein means the occurrence of any of the following events&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:24.69pt">a material breach by Executive of any of the terms and conditions of this Agreement&#59; provided that, if curable, Executive shall have a reasonable period of time (which in no event shall exceed 45 days) during which to cure such material breach following the date on which Executive receives the Company&#8217;s written notice of such material breach&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:21.36pt">Executive&#8217;s reporting to work (A) intoxicated (other than Executive&#8217;s reasonable use of alcohol in connection with business entertainment, provided, that such use of alcohol does not cause the Company or any of its Subsidiaries or Affiliates substantial public disgrace or disrepute or economic harm) or (B) under the influence of illegal drugs&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:18.03pt">Executive&#8217;s use of illegal drugs (whether or not at the workplace) or other conduct causing the Company or any of its Subsidiaries or Affiliates substantial public disgrace or disrepute or economic harm&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">(iv)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:18.69pt">breach of fiduciary duty, gross negligence or willful misconduct with respect to the Company or any of its Subsidiaries or Affiliates&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">(v)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.02pt">chronic absenteeism, which shall be deemed to have occurred if Executive has at least ten absences unrelated to paid time off, disability or illness in any ten week period&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">(vi)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:18.69pt">Executive&#8217;s material failure or willful refusal to substantially perform his duties, responsibilities and functions&#59; provided that, if curable, Executive shall have a reasonable period of time (which in no event shall exceed 45 days) during which to cure such failure following the date on which Executive receives the Company&#8217;s written notice of such failure&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">(vii)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:15.36pt">Executive&#8217;s failure to comply with any of the Company&#8217;s or any of its Subsidiaries&#8217; written guidelines or procedures promulgated by the Company or any such Subsidiary and furnished to Executive, including, without limitation, any guidelines or procedures relating to marketing or community relations&#59; provided that, if curable, Executive shall have a reasonable period of time (which in no event shall exceed 45 days) during which to cure such failure following the date on which Executive receives the Company&#8217;s written notice of such failure&#59; or</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">(viii)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:12.03pt">Executive has committed an act or acts constituting a felony or any other act or omission involving theft, dishonesty or fraud against the Company or any of its Subsidiaries or any of their respective customers or suppliers or other business relationships.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.7pt">A &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Change in Control</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; shall be deemed to have occurred upon any of the following events, provided that, to the extent required by Section 409A, such events would also qualify as a &#8220;change in control event&#8221; under Treas. Reg. &#167;1.409A-3(i)(5)&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:24.69pt">Upon the closing of a reorganization, merger, share exchange or consolidation, other than a reorganization, merger, share exchange or consolidation with respect to which those persons who were the beneficial owners, immediately prior to such reorganization, merger, share exchange or consolidation, of outstanding securities of the Company ordinarily having the right to </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;-4-</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">vote in the election of directors own, immediately after the closing of such transaction, more than 51% of the outstanding securities of the resulting corporation ordinarily having the right to vote in the election of directors&#59; or</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:21.36pt">Upon approval by the stockholders of a complete liquidation and dissolution of the Company or the sale or other disposition of all or substantially all of the assets of the Company other than to a Subsidiary or Affiliate.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">(f)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:24.03pt;text-decoration:underline">Termination by Executive</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.  Executive has the right to terminate his employment under this Agreement at any time, for any or no reason, but only after giving the Company (i) 30 days prior written notice with respect to any termination without Good Reason or (ii) the number of days prior written notice set forth in the last sentence of Section 4(b) with respect to any termination with Good Reason.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">(g)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Compensation after Termination</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:24.69pt">If the Employment Period is terminated pursuant to Executive&#8217;s resignation without Good Reason, death or Incapacity, Executive shall only be entitled to receive his Base Salary through the date of termination and shall not be entitled to any other salary, bonus, compensation or benefits from the Company or its Subsidiaries, except as may be required by applicable law.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:21.36pt">If the Employment Period is terminated by the Company for Cause, Executive shall only be entitled to his Base Salary through the date of termination and shall not be entitled to any other salary, bonus, compensation or benefits from the Company or its Subsidiaries, except as may be required by applicable law.  In addition, in such event, Executive shall automatically forfeit any rights to any unvested equity owned by Executive in the Company or any Subsidiary.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:18.03pt">If the Employment Period is terminated by the Company without Cause or by Executive for Good Reason, then subject to the conditions described in Section 4(g)(v) below, Executive shall be entitled to receive as severance compensation the following (collectively, &#8220;Severance Pay&#8221;)&#58; (A) an amount equal to twelve (12) months of Executive&#8217;s then-current annual Base Salary, payable in regular installments beginning within 30 days following the Termination Date in accordance with the Company&#8217;s general payroll practices for salaried employees&#59; (B) continuation of the welfare benefits described in Section 3(b) for twelve (12) months to the extent permissible under the terms of the relevant benefit plans at the same cost to Executive as if Executive were an active employee of the Company&#59; (C) the Bonus payable to Executive within 3 months after the end of the applicable year (to the extent not previously paid), paid in a lump sum at the time that bonuses are regularly paid to employees&#59; (D) any awarded but unpaid Annual Bonus for the prior year&#59; (E) with respect to the portion of each restricted stock award held by Executive as of date on which the Employment Period is terminated that is subject to time-based vesting (the &#8220;Time-Based RSA&#8221;), accelerated vesting of the Time-Based RSA to the vesting event next following the date on which the Employment Period is terminated&#59; (F) with respect to the portion of each performance stock unit award held by the Executive as of the date on which the Employment Period is terminated that has been converted into &#8220;earned shares&#8221; (the &#8220;Earned PSUs&#8221;), accelerated vesting of the Earned PSUs to the vesting event next following the date on which the Employment Period is terminated&#59; and (G) with respect to each performance stock unit award held by Executive as of the date on which the Employment Period ends that have not been converted to Earned PSUs, the Executive&#8217;s rights under the award will be fully vested based on the number of shares that would be earned under the award based on performance measured through the end of the Employment Period.  For purposes of this Section 4(g), &#8220;Bonus&#8221; shall mean an amount equal to Executive&#8217;s then-current annual Base Salary, multiplied by the percentage contained in Section 3(d) hereof.  For the avoidance of doubt, the unvested portion of any restricted stock awards and performance share unit awards held by Executive as of the date </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;-5-</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">on which the Employment Period ends (after giving effect to the acceleration provisions set forth in subsections (D) and (E) herein and the terms and conditions of the applicable award agreements and the Surgery Partners, Inc. 2015 Omnibus Incentive Plan (as amended from time to time)) shall be forfeited and of no further force and effect.  </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">(iv)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:18.69pt">If, within 90 days prior to or 12 months following a Change in Control, either (A) the Company terminates the employment of Executive hereunder without Cause under Section 4(a) above, or (B) Executive terminates his employment for Good Reason under Section 4(b) above, then, in lieu of any other compensation that may be specified in this Agreement, the Company will pay Executive the Severance Pay in a single lump-sum payment not later than 30 days after termination.  If any payment obligation under this Section 4(g) arises, no compensation received from other employment (or otherwise) will reduce the Company&#8217;s obligation to make the payment(s) described in this paragraph.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">(v)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.02pt">Notwithstanding Sections 4(g)(iii) or (iv), Executive&#8217;s right to receive Severance Pay hereunder is conditioned upon&#58; (A) Executive executing, and not revoking, a written separation agreement and general release of all claims against the Company, its Subsidiaries and Affiliates and their respective managers, directors, officers, shareholders, members, representatives, agents, attorneys, predecessors, successors and assigns (other than a claim for the severance payments described in Section 4(g)(iii) or (iv) and Executive&#8217;s rights to future distributions and payments related to the continued ownership of any equity securities in the Company that Executive will continue to own after such termination), in form and substance acceptable to the Company, which shall among other things, contain a general release by Executive of all claims arising out of his employment and termination of employment by the Company (a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Release Agreement</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) within 30 days of Executive&#8217;s Termination Date&#59; and (B) Executive&#8217;s material compliance with all of his obligations which survive termination of this Agreement.  The Severance Pay is intended to be in lieu of all other payments to which Executive might otherwise be entitled in respect of his termination without Cause or resignation with Good Reason.  The Company and its Subsidiaries and Affiliates shall have no further obligations hereunder or otherwise with respect to Executive&#8217;s employment from and after the date of termination of employment with the Company (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Termination Date</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), and the Company and its Subsidiaries and Affiliates shall continue to have all other rights available hereunder (including without limitation, all rights hereunder at law or in equity).</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">(vi)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:18.69pt">Nothwithstanding the foregoing, the Release Agreement (x) shall not require the release of Executive&#8217;s rights arising from the express terms of this Agreement or any applicable award agreement that are associated with a termination of employment&#59; (y) shall not impose any postemployment restricttions other than those set forth in this Agreement, and (z) shall take into account and preserve Executive&#8217;s rights in the event that a Change of Control occurs within 90 days after termination of employment (or such longer tail period as may be provided by any agreement between Executive and the Company). </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">(vii)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:15.36pt">Except as otherwise expressly provided herein, all of Executive&#8217;s rights to salary, bonuses, benefits and other compensation hereunder which might otherwise accrue or become payable after the termination of the Employment Period shall cease upon such termination, other than those expressly required under applicable law (such as COBRA).  All amounts payable to Executive as severance hereunder shall be subject to all required withholdings by the Company.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">(h)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.02pt">The Company may offset any amount Executive owes the Company or its Subsidiaries or Affiliates against any amount they or their Subsidiaries or Affiliates owe Executive hereunder.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">5.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Confidential Information</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.  Other than in the performance of his duties hereunder, during the Restrictive Period (as defined below) and thereafter, Executive shall keep secret and retain in strictest confidence, and shall not, without the prior written consent of the Company, furnish, make available or </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;-6-</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">disclose to any third party or use for the benefit of herself or any third party, any Confidential Information.  As used in this Agreement, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Confidential Information</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; shall mean any information relating to the business or affairs of the Company or any of its Subsidiaries or Affiliates or the Business, including but not limited to any technical or non-technical data, formulae, compilations, programs, devices, methods, techniques, designs, processes, procedures, improvements, models, manuals, financial data, acquisition strategies and information, information relating to operating procedures and marketing strategies, and any other proprietary information used by the Company or any of its Subsidiaries or Affiliates in connection with the Business, irrespective of its form&#59; provided, however, that Confidential Information shall not include any information which is in the public domain or becomes known in the industry, in each case through no wrongful act on the part of Executive.  Executive acknowledges that the Confidential Information is vital, sensitive, confidential and proprietary to the Company and its Subsidiaries and Affiliates.  Executive will immediately notify the Company of any unauthorized possession, use, disclosure, copying, removal or destruction, or attempt thereof, of any Confidential Information by anyone of which Executive becomes aware and of all details thereof.  Executive shall take all reasonably appropriate steps to safeguard Confidential Information and to protect it against disclosure, misuse, espionage, loss and theft.  Executive shall deliver to the Company at the termination or expiration of the Employment Period, or at any other time the Company may request, all memoranda, notes, plans, records, reports, computer tapes, computers, printouts and software and other documents and data (and copies thereof) embodying or relating to the Confidential Information, Inventions and Discoveries (as defined below) or the business of the Company or any of its Subsidiaries or Affiliates which Executive may then possess or have under his control.  Nothing in this Agreement limits, restricts or in any other way affects Executive&#8217;s communicating with any governmental agency or entity, or communicating with any official or staff person of a governmental agency or entity, concerning matters relevant to the governmental agency or entity, or requires Executive to provide notice to the Company of the same.  Executive cannot be held criminally or civilly liable under any federal or state trade secret law for disclosing a trade secret (1) in confidence to a federal, state, or local government official, either directly or indirectly, or to an attorney, solely for the purpose of reporting or investigating a suspended violation of law, or (2) in a compliant or other document filed under seal in a lawsuit or other proceeding.  Notwithstanding this immunity from liability, Executive may be held liable if Executive unlawfully accesses trade secrets by unauthorized means.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Business</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; as used herein means the business of owning, operating, developing and&#47;or managing, or providing management or administrative services to, (a) ambulatory surgery centers anywhere in the United States or (b) physician-owned surgical hospitals within a 50 mile radius of any hospital that is owned, operated, developed or managed by the Company or any Affiliate.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">6.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Inventions and Discoveries</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.7pt">Executive understands and agrees that all inventions, discoveries, ideas, improvements, whether patentable, copyrightable or not, pertaining to the Business or relating to Company&#8217;s or any of its Subsidiaries&#8217; or Affiliates&#8217; actual or demonstrably anticipated research, development or inventions (collectively, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Inventions and Discoveries</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) that result from any work performed by Executive solely or jointly with others for the Company or any of its Subsidiaries or Affiliates which Executive, solely or jointly with others, conceives, develops, or reduces to practice during the course of Executive&#8217;s employment with the Company or any of its Subsidiaries, are the sole and exclusive property of the Company.  Executive will promptly disclose all such matters to the Company and will assist the Company in obtaining legal protection for Inventions and Discoveries.  Executive hereby agrees on behalf of herself, his executors, legal representatives and assignees that he will assign, transfer and convey to the Company, its successors and assigns the Inventions and Discoveries.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.02pt">THE COMPANY AND EXECUTIVE ACKNOWLEDGE AND AGREE THAT SECTION 6(a) SHALL NOT APPLY TO AN INVENTION OF EXECUTIVE FOR WHICH NO EQUIPMENT, SUPPLIES, FACILITY OR TRADE SECRET INFORMATION OF THE COMPANY </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;-7-</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">OR ANY OF ITS SUBSIDIARIES WAS USED AND WHICH WAS DEVELOPED ENTIRELY ON EXECUTIVE&#8217;S OWN TIME, UNLESS (A) THE INVENTION RELATED (I) TO THE BUSINESS OF THE COMPANY OR ANY OF ITS SUBSIDIARIES OR AFFILIATES OR (II) TO THE COMPANY&#8217;S OR ANY OF ITS SUBSIDIARIES&#8217; OR AFFILIATES&#8217; ACTUAL OR DEMONSTRABLY ANTICIPATED RESEARCH OR DEVELOPMENT, OR (B) THE INVENTION RESULTS FROM ANY WORK PERFORMED BY EXECUTIVE FOR THE COMPANY OR ANY OF ITS SUBSIDIARIES OR AFFILIATES.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.7pt">EXECUTIVE ACKNOWLEDGES THAT HE HAS READ THIS SECTION 6 AND FULLY UNDERSTANDS THE LIMITATIONS WHICH IT IMPOSES UPON HIM AND HAS RECEIVED A DUPLICATE COPY OF THIS AGREEMENT FOR HIS RECORDS.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">7.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Restrictive Covenants</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.  Executive acknowledges that in the course of his employment with the Company or any of its Subsidiaries or Affiliates, or their predecessors or successors, he has been and will be given access to and has and will become familiar with their trade secrets and with other Confidential Information and that his services have been and shall be of special, unique and extraordinary value to the Company and its Subsidiaries or Affiliates.  Therefore, and in further consideration of the compensation to be paid to Executive hereunder and in connection with his employment, and to protect the Company&#8217;s and its Subsidiaries&#8217; and Affiliates&#8217; Confidential Information, business interests and goodwill&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">Non-compete</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.  Executive hereby agrees that for a period commencing on the date hereof and ending on the Termination Date, and thereafter, through the period ending twelve (12) months after the Termination Date (collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Restrictive Period</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), he shall not, directly or indirectly, as employee, agent, consultant, stockholder, director, co-partner or in any other individual or representative capacity, own, operate, manage, control, engage in, invest in or participate in any manner in, act as a consultant or advisor to, render services for (alone or in association with any person, firm, corporation or entity), or otherwise assist any person or entity (other than the Company and its Subsidiaries) that engages in or owns, invests in, operates, manages or controls any venture or enterprise that directly or indirectly engages or is actively developing or attempting to develop in any element of the Business anywhere within a 50-mile radius of the Nashville, Tennessee metropolitan area or within a 50-mile radius of any area (or in the event such area is a major city, the metropolitan area relating to such city) in which the Company or any of its Subsidiaries on the Termination Date actively engages or is actively developing or attempting to develop in any element of the Business (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Territory</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;)&#59; provided, however, that nothing contained herein shall be construed to prevent Executive from investing in the stock of any competing corporation listed on a national securities exchange or traded in the over-the-counter market, but only if Executive is not involved in the business of said corporation and if Executive and his associates (as such term is defined in Regulation 14(A) promulgated under the Securities Exchange Act of 1934, as in effect on the date hereof), collectively, do not own more than an aggregate of 3% of the stock of such corporation.  With respect to the Territory, Executive specifically acknowledges that the Company and its Subsidiaries intend to expand the Business into and throughout the United States. </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">Notwithstanding the foregoing, the activity proscribed by this Section 7(a) shall not constitute a violation of this Section 7(a) where performed for (x) an entity or division or subsidiary or affiliate of an entity (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Division</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) where no more than a </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">de minimis </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">amount of revenue from such entity or Division, as applicable, is derived from a business that is competitive with the business of the Company or any of its Affiliates even if other Divisions of such entity, or the entity or other Divisions as a consolidated group, derives more than a </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">de minimis</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%"> amount of revenue that is competitive with the business of the Company or any of its Affiliates&#59; or (y) an entity that derives no more than $100 million in revenue from one or more divisions, departments or segments, in the aggregate, that are engaged in any business competitive with the business of the Company or any of its Affiliates&#59; provided, that in either case, you are not responsible for (and do not engage or participate in) the day-to-day management, oversight or supervision of such business and provided you do not have direct supervision over the individual or individuals who are so responsible for such day-to-day management, oversight or supervision.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;-8-</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Interference with Relationships</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.  Without limiting the generality of the provisions of Section 7(a) hereof, Executive hereby agrees that, for a period commencing on the Commencement Date and ending on the Termination Date, and thereafter, through the period ending twelve (12) months after the Termination Date (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Non-Solicit Restrictive Period</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), he will not, directly or indirectly, as employee, agent, consultant, stockholder, director, partner or in any other individual or representative capacity, (i) solicit or encourage, or participate in any business which solicits or encourages (A) any person, firm, corporation or other entity which has executed, or proposes to execute, a management services agreement or other services agreement with the Company or any of its Subsidiaries at any time during the term of this Agreement, or any successor in interest to any such person, firm, corporation or other entity, for the purpose of securing business or contracts related to any element of the Business, or (B) any present customer or patient of the Company or any of its Subsidiaries or any of their Affiliated Practices to terminate or otherwise alter his, her or its relationship with the Company or any of its Subsidiaries or such Affiliated Practice&#59; provided, however, that nothing contained herein shall be construed to prohibit or restrict Executive from soliciting business from any such parties on behalf of the Company or any of its Subsidiaries in performance of his duties as an employee of the Company required under and as specifically contemplated by Section 2 above or (ii) divert, entice away, solicit or encourage, or attempt to divert, entice away, solicit or encourage, any physician who utilizes or has invested in an Affiliated Practice to become an owner, investor or user of another practice or facility that is not an Affiliated Practice or approach any such physician for any of the foregoing purposes or authorize or assist in the taking of any such action by any third party.  In addition, at all times from and after the Termination Date, Executive shall not contact or communicate in any manner with any of Company&#8217;s, or any of its Subsidiaries&#8217; or Affiliates&#8217; suppliers or vendors, or any other third party providing services to the Company or any of its Subsidiaries, regarding the Company or any of its Subsidiaries or any Company- or any such Subsidiary-related matter (which suppliers, vendors or third party service providers will include, without limitation, any third party with whom the Company or any of its Subsidiaries was, during the term of Executive&#8217;s employment with the Company or any of its Subsidiaries, contemplating engaging, or negotiating with, for the future provision of products or services). Provided, however, that these restrictions shall apply (x) only with respect to those persons who are or have been a business partner of the Company or any of its Affiliates at any time within the immediate preceding two (2)-year period or whose business has been solicited on behalf of the Company or any of the Affiliates by any of their officers, employees or agents within such two (2)-year period, other than by form letter, blanket mailing or published advertisement, and (y) only if Executive has performed work for such person during his employment with the Company or one of its Affiliates or been introduced to, or otherwise had contact with, such person as a result of his employment or other associations within the Company or one of its Affiliates or have had access to Confidential Information which would assist in his solicitation of such person.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">Non-solicitation</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.  Other than in the performance of his duties hereunder, during the Non-Solicit Restrictive Period, Executive shall not, directly or indirectly, as employee, agent, consultant, stockholder, director, co partner or in any other individual or representative capacity, employ, recruit or solicit for employment or engagement, any person who is employed or engaged by the Company or any of its Subsidiaries or any of its Affiliated Practices during the Non- Solicit Restrictive Period, or otherwise seek to influence or alter any such person&#8217;s relationship with any of the Affiliated Practices, the Company or any of its Subsidiaries&#59; provided, however that responses to a general solicitation (such as an internet or newspaper solicitation) that are not targeted towards any particular person shall not be deemed to be a violation of the restrictions set forth in this Section 7(c).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Affiliated Practice</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.  For purposes of this Agreement, an &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Affiliated Practice</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; shall include any practice or facility (i) in which the Company or any of its Subsidiaries has an ownership interest or (ii) that is managed by or receives other services from the Company or any of its Subsidiaries in connection with any element of the Business.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">Blue Pencil</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.  If any court of competent jurisdiction shall at any time deem the term of this Agreement or any particular Restrictive Covenant (as defined below) too lengthy or the Territory too </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;-9-</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">extensive, the other provisions of this Section 7 shall nevertheless stand, the Restrictive Period herein shall be deemed to be the longest period permissible by law under the circumstances and the Territory herein shall be deemed to comprise the largest territory permissible by law under the circumstances.  The court in each case shall reduce the time period and&#47;or Territory to permissible duration or size.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">(f)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:24.03pt;text-decoration:underline">Covenant Not to Disparage</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.  During the Restrictive Period and thereafter, Executive shall not disparage, denigrate or derogate in any way, directly or indirectly, the Company, any of its Subsidiaries or Affiliates, or any of its or their respective agents, officers, directors, employees, parent, subsidiaries, affiliates, Affiliated Practices, affiliated doctors (including any physicians who utilize or have invested in any Affiliated Practice), representatives, attorneys, executors, administrators, successors and assigns (collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Protected Parties</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), nor shall Executive disparage, denigrate or derogate in any way, directly or indirectly, his experience with any Protected Party, or any actions or decisions made by any Protected Party. Additionally, the Company shall inform its Board of Directors and executive leadership team that, during the Restrictive Period, the members of the Board of Directors and the executive leadership team should not disparage, denigrate or derogate in any way, the Executive.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">(g)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Remedies</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.  Executive acknowledges and agrees that the covenants set forth in this Section 7 and the preceding Sections 5 and 6 (collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Restrictive Covenants</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) are reasonable and necessary for the protection of the business interests of the Company and its Subsidiaries and Affiliates, that irreparable injury may result to the Company and its Subsidiaries and Affiliates if Executive breaches any of the terms of said Restrictive Covenants, and that in the event of Executive&#8217;s actual or threatened breach of any such Restrictive Covenants, the Company and its Subsidiaries and Affiliates will have no adequate remedy at law.  Executive accordingly agrees that in the event of any actual or threatened breach by him of any of the Restrictive Covenants, the Company and its Subsidiaries and Affiliates shall be entitled to immediate temporary injunctive and other equitable relief subject to hearing as soon thereafter as possible.  Nothing contained herein shall be construed as prohibiting the Company or any of its Subsidiaries or Affiliates from pursuing any other remedies available to it for such breach or threatened breach, including the recovery of any damages which it is able to prove.  In addition and supplementary to other rights and remedies existing in its (or their) favor, in the event of the material breach by Executive of any of the provisions of this Section 7, the Company (and&#47;or its Subsidiaries or Affiliates) shall be entitled to require Executive to account for and pay over to the Company (and&#47;or its Subsidiaries or Affiliates) all compensation, profits, moneys, accruals, increments or other benefits actually derived from or received as a result of any transactions constituting a breach of the covenants contained in this Agreement which may require Executive to repay any severance.  In addition, in the event of an alleged breach or violation by Executive of this Section 7, the restricted periods set forth in this Section 7 shall be tolled until such breach or violation has been duly cured.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">(h)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.02pt">Executive understands that the foregoing restrictions may limit his ability to earn a livelihood in a business similar to the business of the Company and its Subsidiaries or Affiliates, but he nevertheless believes that he has received and will receive sufficient consideration and other benefits as an executive of the Company and as otherwise provided hereunder to clearly justify such restrictions which, in any event (given his education, skills and ability), Executive does not believe would prevent him from otherwise earning a living.  Executive acknowledges that the Restrictive Covenants are reasonable and that he has reviewed the provisions of this Agreement with his legal counsel.  Executive shall inform any prospective or future employer of any and all restrictions contained in this Agreement and provide such employer with a copy of such restrictions, prior to the commencement of that employment.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">8.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Executive&#8217;s Representations and Covenants</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.7pt">Executive hereby represents and warrants to the Company that (i) the execution, delivery and performance of this Agreement by Executive do not and shall not conflict with, breach, violate or cause a default under any contract, agreement, instrument, order, judgment or decree to which Executive is a party or by which he is bound, (ii) Executive is not a party to or bound by any employment </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;-10-</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">agreement, non-compete agreement or confidentiality agreement with any other person or entity and (iii) upon the execution and delivery of this Agreement by the Company, this Agreement shall be the valid and binding obligation of Executive, enforceable in accordance with its terms.  Executive hereby acknowledges and represents that he has consulted with independent legal counsel regarding his rights and obligations under this Agreement and that he fully understands the terms and conditions contained herein.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.02pt">During the Employment Period and thereafter, Executive shall cooperate with the Company and its Subsidiaries and Affiliates in any internal investigation or administrative, regulatory or judicial proceeding as reasonably requested by the Company (including, without limitation, Executive being available to the Company upon reasonable notice for interviews and factual investigations, appearing at the Company&#8217;s request to give testimony without requiring service of a subpoena or other legal process, volunteering to the Company all pertinent information and turning over to the Company all relevant documents which are in or may come into Executive&#8217;s possession, all at times and on schedules that are reasonably consistent with Executive&#8217;s other permitted activities and commitments).  In the event the Company requires Executive&#8217;s cooperation in accordance with this Section 8(b), the Company shall reimburse Executive for reasonable travel expenses (including, without limitation, travel expenses, lodging and meals, and reasonable attorneys&#8217; fees upon submission of receipts).  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">9.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Survival</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.  Sections 4 through 22 shall survive and continue in full force in accordance with their terms notwithstanding the expiration or termination of the Employment Period.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">10.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Notices</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.  Any notices provided for in this Agreement shall be in writing and shall be effective when delivered in person or deposited in the United States mail, postage prepaid, and addressed to Executive at his last known address on the books of the Company or, in the case of the Company, to it at its principal place of business, attention of the Chief Executive Officer, or to such other address as either party may specify by notice to the other actually received.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">11.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Severability</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.  Whenever possible, each provision of this Agreement will be interpreted in such manner as to be effective and valid under applicable law, but if any provision of this Agreement is held to be invalid, illegal or unenforceable in any respect under any applicable law or rule in any jurisdiction, such invalidity, illegality or unenforceability will not affect any other provision or any other jurisdiction, but this Agreement will be reformed, construed and enforced in such jurisdiction as if such invalid, illegal or unenforceable provision had never been contained herein.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">12.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Complete Agreement</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.  This Agreement, those documents expressly referred to herein and other documents of even date herewith, embody the complete agreement and understanding among Executive and the Company and its Subsidiaries and, as of the Effective Date, shall supersede and preempt any prior understandings, agreements or representations by or among the parties, written or oral, which may have related to the subject matter hereof in any way, including, for the avoidance of doubt, the Former Employment Agreement.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">13.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">No Strict Construction</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.  The language used in this Agreement will be deemed to be the language chosen by the parties hereto to express their mutual intent, and no rule of strict construction will be applied against any party hereto.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">14.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Counterparts</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.  This Agreement may be executed in separate counterparts (including by facsimile or PDF signature pages), each of which is deemed to be an original and all of which taken together constitute one and the same agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">15.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Successors and Assigns</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.  This Agreement is intended to bind and inure to the benefit of and be enforceable by Executive and the Company and its successors and permitted assigns.  Executive may not assign any of his rights or obligations hereunder without the prior written consent of the Company.  The Company may (a) assign any or all of its respective rights and interests hereunder to one </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;-11-</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">or more Subsidiaries or Affiliates of the Company, (b) designate one or more Subsidiaries or Affiliates of the Company to perform its obligations hereunder (in any or all of which cases the Company nonetheless shall remain responsible for the performance of all of its obligations hereunder), (c) assign its rights hereunder in connection with the sale of all or a substantial part of the business or assets of the Company or one of its Subsidiaries (whether by merger, sale of stock or assets, recapitalization or otherwise) and (d) merge any of the Subsidiaries or Affiliates with or into the Company (or vice versa).  The rights of the Company hereunder are enforceable by the Company or its Subsidiaries or Affiliates, which are the intended third party beneficiaries hereof and no other third party beneficiary is so otherwise intended.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">16.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Delivery by Facsimile or PDF</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.  This Agreement and any amendments hereto, to the extent signed and delivered by means of a facsimile machine or PDF, shall be treated in all manner and respects as an original agreement or instrument and shall be considered to have the same binding legal effect as if it were the original signed version thereof delivered in person.  At the request of any party hereto, each other party hereto shall re-execute original forms thereof and deliver them to the other party.  No party hereto shall raise the use of a facsimile machine or PDF to deliver a signature or the fact that any signature or agreement or instrument was transmitted or communicated through the use of a facsimile machine or PDF as a defense to the formation or enforceability of a contract and each such party forever waives any such defense.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">17.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Income Tax Treatment</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.  Executive and the Company acknowledge that it is the intention of the Company to deduct all cash amounts paid under this Agreement as ordinary and necessary business expenses for income tax purposes.  Executive agrees and represents that he will treat all such non-reimbursable amounts as ordinary income for income tax purposes, and should he report such amounts as other than ordinary income for income tax purposes, he will indemnify and hold the Company harmless from and against any and all taxes, penalties, interest, costs and expenses, including reasonable attorneys&#8217; and accounting fees and costs, which are incurred by Company directly or indirectly as a result thereof.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">18.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Governing Law</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.  This Agreement shall be construed and enforced in accordance with, and all questions concerning the construction, validity, interpretation and performance of this Agreement shall be governed by, the laws of the state in which Executive resides, without giving effect to provisions thereof regarding conflict of laws.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">19.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Waiver of Jury Trial</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.  THE PARTIES HERETO HEREBY WAIVE THEIR RESPECTIVE RIGHTS TO A JURY TRIAL OF ANY CLAIM OR CAUSE OF ACTION BASED UPON OR ARISING OUT OF THIS AGREEMENT.  THE PARTIES HERETO ALSO WAIVE ANY BOND OR SURETY OR SECURITY UPON SUCH BOND WHICH MIGHT, BUT FOR THIS WAIVER, BE REQUIRED OF THE OTHER PARTY.  THE PARTIES HERETO ACKNOWLEDGE THAT THIS WAIVER IS A MATERIAL INDUCEMENT TO ENTER INTO A BUSINESS RELATIONSHIP, THAT EACH HAS ALREADY RELIED ON THE WAIVER IN ENTERING INTO THIS AGREEMENT AND THAT EACH WILL CONTINUE TO RELY ON THE WAIVER IN THEIR RELATED FUTURE DEALINGS.  THE COMPANY AND EXECUTIVE FURTHER WARRANT AND REPRESENT THAT EACH HAS REVIEWED THIS WAIVER WITH THEIR RESPECTIVE LEGAL COUNSEL, AND THAT EACH KNOWINGLY AND VOLUNTARILY WAIVES THEIR RESPECTIVE JURY TRIAL RIGHTS FOLLOWING CONSULTATION WITH LEGAL COUNSEL.  THIS WAIVER IS IRREVOCABLE, MEANING THAT IT MAY NOT BE MODIFIED EITHER ORALLY OR IN WRITING, AND THE WAIVER SHALL APPLY TO ANY SUBSEQUENT AMENDMENTS, RENEWALS, SUPPLEMENTS OR MODIFICATIONS TO THIS AGREEMENT OR TO ANY OTHER DOCUMENTS OR AGREEMENTS RELATING TO THE TRANSACTION CONTEMPLATED HEREBY.  IN THE EVENT OF LITIGATION, THIS AGREEMENT MAY BE FILED AS A WRITTEN CONSENT TO A TRIAL BY THE COURT.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">20.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Consent to Jurisdiction</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;-12-</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.7pt">THE COMPANY AND EXECUTIVE HEREBY CONSENT TO THE JURISDICTION OF ANY STATE OR FEDERAL COURT LOCATED WITHIN THE STATE IN WHICH EXECUTIVE RESIDES AND IRREVOCABLY AGREE THAT SUBJECT TO THE COMPANY&#8217;S ELECTION, ALL ACTIONS OR PROCEEDINGS ARISING OUT OF OR RELATING TO THIS AGREEMENT SHALL BE LITIGATED IN SUCH COURTS.  EXECUTIVE ACCEPTS FOR HERSELF AND IN CONNECTION WITH HIS PROPERTIES, GENERALLY AND UNCONDITIONALLY, THE NONEXCLUSIVE JURISDICTION OF THE AFORESAID COURTS AND WAIVES ANY DEFENSE OF FORUM NON CONVENIENS, AND IRREVOCABLY AGREES TO BE BOUND BY ANY JUDGMENT RENDERED THEREBY IN CONNECTION WITH THIS AGREEMENT.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.02pt">Notwithstanding Section 20(a), the parties intend to and hereby confer jurisdiction to enforce the covenants contained in Sections 5 through 7 upon the courts of any jurisdiction within the geographical scope of such covenants.  If the courts of any one or more of such jurisdictions hold such covenants wholly or partially invalid or unenforceable by reason of the breadth of such scope or otherwise, it is the intention of the parties that such determination not bar or in any way affect the Company&#8217;s right to the relief provided above in the courts of any other jurisdiction within the geographical scope of such covenants, as to breaches of such covenants in such other respective jurisdictions, such covenants as they relate to each jurisdiction being, for this purpose, severable into diverse and independent covenants.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">21.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Amendment and Waiver</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.  Any provision of this Agreement may be amended or waived only with the prior written consent of the Company and Executive, and no course of conduct or course of dealing or failure or delay by any party hereto in enforcing or exercising any of the provisions of this Agreement shall affect the validity, binding effect or enforceability of this Agreement or be deemed to be an implied waiver of any provision of this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">22.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Section 409A</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.  To the maximum extent permitted by law, this Agreement shall be interpreted in such a manner that the payments to Executive under this Agreement are either exempt from, or comply with, Section 409A, including without limitation any such regulations or other guidance that may be issued after the date hereof.  For purposes of Section 409A, each payment made under this Agreement shall be treated as a separate payment and the right to a series of installment payments under this Agreement is to be treated as a right to a series of separate payments.  Notwithstanding anything to the contrary in this Agreement, if Executive is a &#8220;specified employee&#8221; as defined below, as of Executive&#8217;s termination of employment, then, to the extent any payment under this Agreement resulting from Executive&#8217;s termination of employment constitutes deferred compensation (after taking into account any applicable exemptions from Section 409A) and to the extent required by Section 409A, no payments due under this Agreement as a result of Executive&#8217;s termination of employment may be made until the earlier of (a) the first day following the six-month anniversary of Executive&#8217;s date of termination and (b) Executive&#8217;s date of death&#59; provided, however, that any payments delayed during this six-month period shall be paid in the aggregate in a lump sum as soon as reasonably practicable following the sixth month anniversary of Executive&#8217;s date of termination.  For purposes of this Agreement, all references to &#8220;termination of employment&#8221; and correlative phrases shall be construed to require a &#8220;separation from service&#8221; (as defined in Treas. Reg. &#167;1.409A-1(h) after giving effect to the presumptions contained therein), and the term &#8220;specified employee&#8221; means an individual determined by the Company to be a specified employee under Treas. Reg. &#167;409A-1(i).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">23.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:21pt">Legal Fees</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">. The Company will reimburse you for legal fees of up to $5,000 incurred in connection with the negotiation and documentation of this Agreement and related documents, which shall be paid within 20 days of presentation.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">*    *    *    *    *    *    *    * </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;-13-</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">IN WITNESS WHEREOF, the parties hereto have executed this Employment Agreement as of the date first written above.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="margin-bottom:12pt;padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">SURGERY PARTNERS, INC.<br><br><br><br>By&#58; </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">&#47;s&#47; Eric Evans&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"><br>      Eric Evans<br>      Chief Executive Officer</font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Accepted and Agreed&#58;<br><br><br></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">&#47;s&#47; Justin Oppenheimer&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"><br>Justin Oppenheimer</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Date&#58; </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">10&#47;27&#47;2025&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;-14-</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>sgry-20251112.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:b54ad9c4-2ac7-45a7-af50-9ccb8cd7b891,g:e49025d9-fcc2-48e1-a74f-bcebcf2d0f82-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:sgry="http://surgerypartners.com/20251112" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://surgerypartners.com/20251112">
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2025" schemaLocation="https://xbrl.sec.gov/dei/2025/dei-2025.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="sgry-20251112_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="sgry-20251112_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://surgerypartners.com/role/Cover">
        <link:definition>0000001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>sgry-20251112_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:b54ad9c4-2ac7-45a7-af50-9ccb8cd7b891,g:e49025d9-fcc2-48e1-a74f-bcebcf2d0f82-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_dei_SolicitingMaterial_3b4ae969-84d3-4f43-acef-48d510f78879_terseLabel_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
    <link:label id="lab_dei_SolicitingMaterial_label_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SolicitingMaterial" xlink:to="lab_dei_SolicitingMaterial" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_WrittenCommunications_4c0342c5-7f34-431b-beaa-0e59e812b37a_terseLabel_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
    <link:label id="lab_dei_WrittenCommunications_label_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_WrittenCommunications" xlink:to="lab_dei_WrittenCommunications" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_ad137ddd-aa46-4d42-a03d-59a1638749e0_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_267958da-0ae6-411e-a208-e71aba90a3dd_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementTenderOffer_b67b3c12-1549-428c-b9f6-d6a4921a1c2b_terseLabel_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementTenderOffer" xlink:to="lab_dei_PreCommencementTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_f8f51ea3-ef16-4fc1-af78-2859fdc64ae5_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_a9874165-e09d-441e-b239-d3bee405ce95_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_4cc7279b-f132-4fa4-abf1-b91c47cc87b1_terseLabel_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementIssuerTenderOffer" xlink:to="lab_dei_PreCommencementIssuerTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_326c7c8f-c6dd-430f-8a75-f8bd0ce8c5f8_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_938b8480-c333-478c-b814-3b934a28eee6_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_bef410f8-9726-41b8-ad1a-433d5472a54c_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_e0052c24-807b-40ab-b52b-ffd205ed1581_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_ca0c4af6-c551-4b4c-aeba-cbdf4d6e5691_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_f68ff81a-5e27-4b8f-86fa-37940b3a5b94_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_30ede34e-7968-40e5-b8bd-773ee8d99aef_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_083a5a94-f2f3-44d5-b0f3-9cfa5e35bfcd_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_33ed7ada-023d-41ff-a0b1-bdace5830699_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_8d197084-3090-42ef-8505-88c5218a6b5b_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_5be06697-4945-458e-985f-39676e7cdbf0_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_88981591-ddba-4adf-bed4-62bbed486bc5_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_eb34100e-5c6d-4097-bb9b-da141c3156aa_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_d64ffa3a-1167-49d1-923c-44f3d6a7d339_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>sgry-20251112_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:b54ad9c4-2ac7-45a7-af50-9ccb8cd7b891,g:e49025d9-fcc2-48e1-a74f-bcebcf2d0f82-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://surgerypartners.com/role/Cover" xlink:type="simple" xlink:href="sgry-20251112.xsd#Cover"/>
  <link:presentationLink xlink:role="http://surgerypartners.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_7a86473f-2ea2-4200-95a4-de76c7f8f291" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_d6c6badc-35aa-4c47-9675-b3d933ae32bd" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7a86473f-2ea2-4200-95a4-de76c7f8f291" xlink:to="loc_dei_EntityCentralIndexKey_d6c6badc-35aa-4c47-9675-b3d933ae32bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_3ef97160-2861-492e-9def-7184b59023f7" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7a86473f-2ea2-4200-95a4-de76c7f8f291" xlink:to="loc_dei_AmendmentFlag_3ef97160-2861-492e-9def-7184b59023f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_ae7164a4-c731-4dec-9aef-07e78424988b" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7a86473f-2ea2-4200-95a4-de76c7f8f291" xlink:to="loc_dei_DocumentType_ae7164a4-c731-4dec-9aef-07e78424988b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_2460ed1f-41b5-4e29-8f50-159a167094b1" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7a86473f-2ea2-4200-95a4-de76c7f8f291" xlink:to="loc_dei_DocumentPeriodEndDate_2460ed1f-41b5-4e29-8f50-159a167094b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_4bcfd215-8e2c-483c-8a48-a77db800800f" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7a86473f-2ea2-4200-95a4-de76c7f8f291" xlink:to="loc_dei_EntityRegistrantName_4bcfd215-8e2c-483c-8a48-a77db800800f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_e1468577-c75e-4961-95e5-a32fc2be856c" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7a86473f-2ea2-4200-95a4-de76c7f8f291" xlink:to="loc_dei_EntityIncorporationStateCountryCode_e1468577-c75e-4961-95e5-a32fc2be856c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_d900e040-dad6-4250-bda9-d4ce897e4164" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7a86473f-2ea2-4200-95a4-de76c7f8f291" xlink:to="loc_dei_EntityFileNumber_d900e040-dad6-4250-bda9-d4ce897e4164" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_33fee20e-a8e1-482a-a082-72489f2bfda6" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7a86473f-2ea2-4200-95a4-de76c7f8f291" xlink:to="loc_dei_EntityTaxIdentificationNumber_33fee20e-a8e1-482a-a082-72489f2bfda6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_678cced1-f981-480b-b229-bc9bce734d2f" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7a86473f-2ea2-4200-95a4-de76c7f8f291" xlink:to="loc_dei_EntityAddressAddressLine1_678cced1-f981-480b-b229-bc9bce734d2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_23616a10-d57f-4c48-9aa3-4bdbe5bb9ea4" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7a86473f-2ea2-4200-95a4-de76c7f8f291" xlink:to="loc_dei_EntityAddressCityOrTown_23616a10-d57f-4c48-9aa3-4bdbe5bb9ea4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_1b331a27-fb6e-4c24-bd9d-2c89bb449e77" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7a86473f-2ea2-4200-95a4-de76c7f8f291" xlink:to="loc_dei_EntityAddressStateOrProvince_1b331a27-fb6e-4c24-bd9d-2c89bb449e77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_0cd08a01-95ed-434a-8d93-474c4a5dfb76" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7a86473f-2ea2-4200-95a4-de76c7f8f291" xlink:to="loc_dei_EntityAddressPostalZipCode_0cd08a01-95ed-434a-8d93-474c4a5dfb76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_bfe340f8-78e0-4e39-9130-3c7ad424480d" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7a86473f-2ea2-4200-95a4-de76c7f8f291" xlink:to="loc_dei_CityAreaCode_bfe340f8-78e0-4e39-9130-3c7ad424480d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_0355edad-7950-4e46-9215-e48eb76623af" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7a86473f-2ea2-4200-95a4-de76c7f8f291" xlink:to="loc_dei_LocalPhoneNumber_0355edad-7950-4e46-9215-e48eb76623af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_5fcae67d-2a6d-4b72-b70f-1cd8136356d2" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7a86473f-2ea2-4200-95a4-de76c7f8f291" xlink:to="loc_dei_WrittenCommunications_5fcae67d-2a6d-4b72-b70f-1cd8136356d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_6f008933-b0d3-4e47-9c69-dccb5c98173d" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7a86473f-2ea2-4200-95a4-de76c7f8f291" xlink:to="loc_dei_SolicitingMaterial_6f008933-b0d3-4e47-9c69-dccb5c98173d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_d412bc97-58d5-4536-b0a3-9c1c90116fb3" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7a86473f-2ea2-4200-95a4-de76c7f8f291" xlink:to="loc_dei_PreCommencementTenderOffer_d412bc97-58d5-4536-b0a3-9c1c90116fb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_db957936-818a-49a7-af8d-4bae65e24a5a" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7a86473f-2ea2-4200-95a4-de76c7f8f291" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_db957936-818a-49a7-af8d-4bae65e24a5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_51927d04-4c7b-4804-91ec-6cb0b87df18a" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7a86473f-2ea2-4200-95a4-de76c7f8f291" xlink:to="loc_dei_Security12bTitle_51927d04-4c7b-4804-91ec-6cb0b87df18a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_81cd430f-0789-442e-a5d0-6bf6a7e491d7" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7a86473f-2ea2-4200-95a4-de76c7f8f291" xlink:to="loc_dei_TradingSymbol_81cd430f-0789-442e-a5d0-6bf6a7e491d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_787425be-ec21-429d-b3f6-2dd252a2da85" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7a86473f-2ea2-4200-95a4-de76c7f8f291" xlink:to="loc_dei_SecurityExchangeName_787425be-ec21-429d-b3f6-2dd252a2da85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_c64e7997-3e89-46f2-b028-976d73c70afd" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7a86473f-2ea2-4200-95a4-de76c7f8f291" xlink:to="loc_dei_EntityEmergingGrowthCompany_c64e7997-3e89-46f2-b028-976d73c70afd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Nov. 12, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001638833<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Nov. 12,  2025<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Surgery Partners, Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-37576<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">47-3620923<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">340 Seven Springs Way, Suite&#160;600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Brentwood<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">TN<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">37027<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">615<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">234-5900<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.01 per share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">SGRY<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.3</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="sgry-20251112.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://surgerypartners.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" original="sgry-20251112.htm">sgry-20251112.htm</File>
    <File>sgry-20251112.xsd</File>
    <File>sgry-20251112_lab.xml</File>
    <File>sgry-20251112_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="25">http://xbrl.sec.gov/dei/2025</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>13
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "sgry-20251112.htm": {
   "nsprefix": "sgry",
   "nsuri": "http://surgerypartners.com/20251112",
   "dts": {
    "inline": {
     "local": [
      "sgry-20251112.htm"
     ]
    },
    "schema": {
     "local": [
      "sgry-20251112.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "sgry-20251112_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "sgry-20251112_pre.xml"
     ]
    }
   },
   "keyStandard": 22,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2025": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 23,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2025": 25
   },
   "report": {
    "R1": {
     "role": "http://surgerypartners.com/role/Cover",
     "longName": "0000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sgry-20251112.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sgry-20251112.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://surgerypartners.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CityAreaCode",
     "presentation": [
      "http://surgerypartners.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://surgerypartners.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentType",
     "presentation": [
      "http://surgerypartners.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://surgerypartners.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://surgerypartners.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://surgerypartners.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://surgerypartners.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, State or Province",
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://surgerypartners.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://surgerypartners.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://surgerypartners.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://surgerypartners.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://surgerypartners.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://surgerypartners.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Tax Identification Number",
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://surgerypartners.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://surgerypartners.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Issuer Tender Offer",
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://surgerypartners.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Tender Offer",
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12bTitle",
     "presentation": [
      "http://surgerypartners.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12(b) Security",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://surgerypartners.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://surgerypartners.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Soliciting Material",
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "TradingSymbol",
     "presentation": [
      "http://surgerypartners.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://surgerypartners.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Written Communications",
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>14
<FILENAME>0001638833-25-000166-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001638833-25-000166-xbrl.zip
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MJ #R0"1]53<Z =D.N ZSL%S%H*'@C8:* ;HYE8-R$=MT*F.RZF5=CHO;8X;
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MU^1VF"ZH] 1##S4>[23UJD_XQ3R>@"-JNU*#MY5ED=MQN[@5XT B3:Z3=)W
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M$LY6^ ^,85@N-]C):0K;G:+R %H9Z#JSL@#FE*L9E8Z)333TM $M,JTT>73
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MG!@WI0 .1Q3.TZ6IW<[V<"<2JF4';^'U$)O1[=%5=:/]M>U2!%S1D'*SR.O
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MIQX4YVQ$#1R/$I@)QJ3A0:B(4BDY1E@]4",.>+DBVU6I%I3W305J8&D;00)
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MTWG'"G@&OB/9G(4\^G9:&BN5-,OEFYL;\\8U8S$JVXU&HZQ;2UG7@/%%Q]E
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MP!'L?C[NI&DY_H&UPKH[$]?LL8N6;YOM' VPX1#-)AT1YZ31E (/MF:JNAV
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MK#!J3=V)G&:DR6!I-5#GHWV!/1(?TB(I'DY-H)PM/QG([O^M'A:,FK-H&(5
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MWJZ)[EG 7X+\-&*!#."%B%OGQ1>O0ZPV8T2OJ<;4\C%BZ/=\AM,/$"/XZ\>
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M(>4U'C@_>?JB?6D?BC\_^1]02P$"% ,4    "  &BVQ;GV+*?JI)   CHP$
M'@              @ $     97AH:6)I=#$P,6]P<&5N:&5I;65R96UP;&\N
M:'1M4$L! A0#%     @ !HML6[TA&[S9#P  KE\  !$              ( !
MYDD  '-G<GDM,C R-3$Q,3(N:'1M4$L! A0#%     @ !HML6])[G,=C @
M @<  !$              ( ![ED  '-G<GDM,C R-3$Q,3(N>'-D4$L! A0#
M%     @ !HML6ZV;@4_["0  ?50  !4              ( !@%P  '-G<GDM
M,C R-3$Q,3)?;&%B+GAM;%!+ 0(4 Q0    (  :+;%O+>Q6ALP8  .0P   5
M              "  :YF  !S9W)Y+3(P,C4Q,3$R7W!R92YX;6Q02P4&
/  4 !0!0 0  E&T

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>sgry-20251112_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="sgry-20251112.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
        </entity>
        <period>
            <startDate>2025-11-12</startDate>
            <endDate>2025-11-12</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-24">0001638833</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="c-1" id="f-25">false</dei:AmendmentFlag>
    <dei:DocumentType contextRef="c-1" id="f-1">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-2">2025-11-12</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="c-1" id="f-3">Surgery Partners, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-4">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="c-1" id="f-5">001-37576</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="c-1" id="f-6">47-3620923</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-7">340 Seven Springs Way, Suite&#160;600</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-8">340 Seven Springs Way, Suite&#160;600</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-9">Brentwood</dei:EntityAddressCityOrTown>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-10">Brentwood</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c-1" id="f-11">TN</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-12">37027</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c-1" id="f-13">615</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-1" id="f-14">234-5900</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="c-1" id="f-15">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="c-1" id="f-16">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="c-1" id="f-17">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="c-1" id="f-18">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="c-1" id="f-19">Common Stock, par value $0.01 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-1" id="f-20">SGRY</dei:TradingSymbol>
    <dei:TradingSymbol contextRef="c-1" id="f-21">SGRY</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-1" id="f-22">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-23">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
